SARASOTA, Fla.—Fred Telling, a director at Oragenics Inc . (NYSE:OGEN), sold 3,597 shares of the company's common stock on December 6, according to a recent SEC filing. The shares were sold at an average price of $0.36 each, amounting to a total transaction value of $1,294. Following this sale, Telling holds 34,748 shares directly. The transaction comes as Oragenics shares have declined over 90% in the past year, with the stock currently trading near $0.35. According to InvestingPro analysis, the company maintains a strong cash position relative to debt, though it faces profitability challenges.
Oragenics, a pharmaceutical company based in Sarasota, Florida, continues to be active in the life sciences sector. The transaction was executed by Julio C. Esquivel, acting as Attorney-in-Fact for Fred Telling. InvestingPro analysis reveals 8 additional investment tips for OGEN, including key insights about its growth prospects and market position. Subscribers can access detailed Fair Value analysis and comprehensive financial metrics.
In other recent news, Oragenics Inc. announced the termination of its President's employment agreement and entered into a sales agreement with Dawson James Securities Inc. for an at-the-market offering of its common stock, potentially reaching up to $10,000,000 in aggregate sales. The company also granted stock options to President J. Michael Redmond and CFO Janet Huffman under its 2021 Equity Incentive Plan. In terms of clinical developments, Oragenics has progressed with ONP-002, a product candidate for the treatment of concussions, which has passed FDA-required cardiotoxicity tests and shown no evidence of causing DNA damage in preclinical studies. The company has also strengthened its leadership team with the appointments of Dr. William 'Frank' Peacock as Chief Clinical Officer and Dr. James 'Jim' Kelly as Chief Medical (TASE:PMCN) Officer. In addition, the company has rescheduled its 2023 Annual Meeting of Shareholders from August to December 2024. These are the recent developments for Oragenics Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.